S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?

Brainstorm Cell Therapeutics (BCLI) Earnings Date, Estimates & Call Transcripts

$0.37
0.00 (0.00%)
(As of 02/28/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

BCLI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BCLI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Brainstorm Cell Therapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate:($0.70) EPS
Next Year EPS Consensus Estimate: ($0.47) EPS

BCLI Earnings Date and Information

Brainstorm Cell Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off prior year's report dates.

Brainstorm Cell Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
4/4/2024
Estimated)
------- 
11/14/2023Q3 2023($0.14)($0.14)-($0.25)--    
8/14/2023Q2 2023($0.15)($0.27)($0.12)($0.27)--
5/15/2023Q1 2023($0.16)($0.14)+$0.02($0.14)--
3/30/2023Q4 2022($0.18)($0.14)+$0.04($0.14)--
11/14/2022Q3 2022($0.15)($0.19)($0.04)($0.19)--
8/15/2022Q2 2022($0.15)($0.19)($0.04)($0.19)--    
5/16/2022Q1 2022($0.13)($0.15)($0.02)($0.15)--    
3/28/2022Q4 2021($0.20)($0.17)+$0.03($0.17)--    
11/15/2021Q3 2021($0.21)($0.15)+$0.06($0.15)--    
8/5/2021Q2 2021($0.24)($0.17)+$0.07($0.17)--    
4/25/2021Q1 2021($0.26)($0.19)+$0.07($0.19)--  












Brainstorm Cell Therapeutics Earnings - Frequently Asked Questions

When is Brainstorm Cell Therapeutics's earnings date?

Brainstorm Cell Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off last year's report dates. Learn more on BCLI's earnings history.

How much profit does Brainstorm Cell Therapeutics generate each year?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a recorded net income of -$24.28 million. BCLI has generated -$0.44 earnings per share over the last four quarters.

What is Brainstorm Cell Therapeutics's EPS forecast for next year?

Brainstorm Cell Therapeutics's earnings are expected to grow from ($0.70) per share to ($0.47) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:BCLI) was last updated on 2/29/2024 by MarketBeat.com Staff